ADXN Stock Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Addex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.073 |
| 52 Week High | CHF0.26 |
| 52 Week Low | CHF0.036 |
| Beta | 1.82 |
| 1 Month Change | -64.22% |
| 3 Month Change | -1.62% |
| 1 Year Change | -47.48% |
| 3 Year Change | -94.93% |
| 5 Year Change | -95.88% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
Mar 03
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
May 11Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)
Jun 10Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Mar 07What Type Of Returns Would Addex Therapeutics'(VTX:ADXN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Jan 12Shareholder Returns
| ADXN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 7.0% | 2.6% | 3.6% |
| 1Y | -47.5% | 11.4% | -0.9% |
Return vs Industry: ADXN underperformed the Swiss Biotechs industry which returned 6.5% over the past year.
Return vs Market: ADXN underperformed the Swiss Market which returned -2.4% over the past year.
Price Volatility
| ADXN volatility | |
|---|---|
| ADXN Average Weekly Movement | 23.1% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: ADXN's share price has been volatile over the past 3 months.
Volatility Over Time: ADXN's weekly volatility has increased from 17% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 23 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd Fundamentals Summary
| ADXN fundamental statistics | |
|---|---|
| Market cap | CHF9.36m |
| Earnings (TTM) | -CHF10.56m |
| Revenue (TTM) | CHF1.65m |
5.7x
P/S Ratio-0.9x
P/E RatioIs ADXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADXN income statement (TTM) | |
|---|---|
| Revenue | CHF1.65m |
| Cost of Revenue | CHF6.94m |
| Gross Profit | -CHF5.29m |
| Other Expenses | CHF5.27m |
| Earnings | -CHF10.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 12, 2024
| Earnings per share (EPS) | -0.082 |
| Gross Margin | -321.08% |
| Net Profit Margin | -640.91% |
| Debt/Equity Ratio | 0% |
How did ADXN perform over the long term?
See historical performance and comparison